Molecular staging for patients with malignant melanoma

Expert Review of Anticancer Therapy

Volumn 7, Issue 11, 2007, Pages 1665-1674

  Shivers, Steve ^a   Jakub, James ^a   Pendas, Solange ^a   Reintgen, Douglas ^a  

^a Lakeland Regional Cancer Center   (United States)

Author keywords

Malignant melanoma; Molecular staging; Prognosis; Sentinel lymph node

Indexed keywords

ALPHA2 INTERFERON; EOSIN; HEMATOXYLIN; ISOSULFAN BLUE; MESSENGER RNA; MONOPHENOL MONOOXYGENASE; PARAFFIN; PROTEIN S 100; TECHNETIUM SULFUR COLLOID TC 99M;

ACCURACY; ADJUVANT THERAPY; ARTICLE; CANCER ADJUVANT THERAPY; CANCER MORTALITY; CANCER RECURRENCE; CANCER STAGING; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE FREE SURVIVAL; EMBEDDING; FOLLOW UP; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INTERMETHOD COMPARISON; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; LYMPHOSCINTIGRAPHY; MEDICAL RESEARCH; MELANOMA; MICROMETASTASIS; MICROSCOPY; MOLECULAR PROBE; OVERALL SURVIVAL; PATIENT MONITORING; POLYMERASE CHAIN REACTION; PREDICTION; PROGNOSIS; RECURRENCE RISK; REPRODUCIBILITY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SENSITIVITY AND SPECIFICITY; SENTINEL LYMPH NODE; TISSUE CULTURE; TUMOR VOLUME;

CHEMOTHERAPY, ADJUVANT; CLINICAL TRIALS AS TOPIC; HUMANS; LYMPHATIC METASTASIS; MELANOMA; NEOPLASM STAGING; NERVE GROWTH FACTORS; PROGNOSIS; RADIONUCLIDE IMAGING; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, NEOPLASM; S100 PROTEINS; SENSITIVITY AND SPECIFICITY; SENTINEL LYMPH NODE BIOPSY; SKIN NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 37349002728     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/14737140.7.11.1665     Document Type: Article

References (26)

1. Ryan L, Kramar A, Borden E. Prognostic factors in metastatic melanoma. Cancer 71, 2995-3005 (1993).
2. Cochran AJ, Wen DR, Morton DL. Occult tumor cells in lymph nodes of patients with pathological stage I melanoma. Am. J. Surg. Pathol. 12, 612-618 (1988).
3. Wong JH, Cagle LA, Morton DL. Lymphatic drainage of skin to sentinel node in a feline model. Ann. Surg. 214, 637-641 (1991).
4. Balch C, Soong SJ, Bartolucci AA et al. Efficacy of an elective regional lymph node dissection of 1-4 mm thick melanomas for patients 60 years of age and younger. Ann. Surg. 224, 255-266 (1996).
5. Cochran AJ, Wen DR, Morton DL. Occult tumor cells in lymph nodes of patients with pathological stage I melanoma. Am. J. Surg. Pathol. 12, 612-618 (1988).
6. Bleicher RJ, Foshag LJ, Essner R, Wanek LA, Morton DL. Sentinel node positivity and characteristics of 'thin' invasive cutaneous melanomas. Presented at: The 54th Annual Cancer Symposium, Society of Surgical Oncology. Washington, DC, USA, 15-18 March 2001 (Abstract).
7. Cho KH, Hashimoto K, Taniguchi Y, Pietruk T, Zarbo RJ, An T. Immunohistochemical study of melanocytic nevus and malignant melanoma with monoclonal antibodies against S-100 subunits. Cancer 66, 765-771 (1990).
8. Wang X, Heller R, VanVoorhis N et al. Detection of submicroscopic lymph node metastases with polymerase chain rection in patients with malignant melanoma. Ann. Surg. 220, 768 (1994).
9. Dessureault S, Soong S, Ross M et al. Improved survival for node-negative patients with intermediate-to-thick melanomas (> 1.0 mm) staged with sentinel lymph node (SLN) biopsy. Presented at: The 54th Annual Cancer Symposium, Society of Surgical Oncology. Washington, DC, USA, 15-18 March 2001 (Abstract).
10. Shivers SC, Wang X, Li W et al. Molecular staging of malignant melanoma: correlation with clinical outcome. JAMA 280, 1410-1415 (1998).
11. Berman C, Norman J, Cruse CW, Reintgen DS, Clark RA. Lymphoscintigraphy in malignant melanoma. Ann. Plast. Surg. 28, 29-32 (1992).
12. Messina J, Glass F. Pathologic examination of the sentinel lymph node. J. Florida Med. Assoc. 84, 153-156 (1997).
13. Li W, Stall A, Shivers SC et al. Clinical relevance of molecular staging for melanoma. Ann. Surg. 231, 795-803 (2000).
14. Heller R, Wassalle J, Becker J et al. The detection of submicroscopic lymph node metastases in patients with malignant melanoma. Arch. Surg. 126, 1455-1460 (1991).
15. Heller R, Becker J, Wassalle J et al. Detection of occult lymph node metastases in malignant melanoma. Ann. Plast. Surg. 28, 74-77 (1992).
16. Heller R, King B, Baekey P, Cruse CW, Reintgen DS. The identification of submicroscopic lymph node metastases in patients with malignant melanoma. Semin. Surg. Oncol. 9, 285-289 (1993).
17. Shivers S, Hoffman S, Lin J, Li W, Stafford M, Reintgen DS. Low specificity for detection of sentinel node micrometastases by a nested RT-PCR assay for tyrosinase in melanoma patients. Presented at: The 54th Annual Cancer Symposium, Society of Surgical Oncology. Washington, DC, USA, 15-18 March 2001 (Abstract).
18. McMasters KM, Edwards M, Ross M et al. SunBelt Melanoma Trial. Frequency of non-sentinel lymph node metastases in melanoma. Presented at: The 54th Annual Cancer Symposium, Society of Surgical Oncology. Washington, DC, USA, 15-18 March 2001 (Abstract).
19. Bieligk SC, Ghossein R, Bhattacharya S, Colt DG. Detection of tyrosinase mRNA by reverse transcription polymerase chain reaction in melanoma sentinel nodes. Ann. Surg. Oncol. 6, 225-226 (1999).
20. Bostick PJ, Morton DL, Turner RR et al. Prognostic significance of occult metastases detected by sentinel lymphadenectomy and reverse transcriptase-polymerase chain reaction in early-stage melanoma patients. J. Clin. Oncol. 17(10), 3238-3244 (1999).
21. Goydos JS, Ravikumar TS, Germino FJ, Yudd A, Bancila E. Minimally invasive staging of patients with melanoma: sentinel lymphadenectomy and detection of the melanoma-specific proteins MART-1 and tyrosinase by reverse transcriptase polymerase chain reaction. J. Am. Coll. Surg. 187(2), 182-188; discussion 188-190 (1998).
22. Curry BJ, Myers K, Hersey P. MART-1 is expressed less frequently on circulating melanoma cells in patients who develop distant compared with locoregional metastases. J. Clin. Oncol. 17(8), 2562-2571 (1999).
23. Scoggins CR, Rosss M, Reintgen DS et al. Prospective multi-institutional study of reverse transcriptase polymerase chain reaction for molecular staging of melanoma. J. Clin. Oncol. 24, 2849-2857 (2006).
24. Kirkwood JM, Strawderman MH, Ernstoff MS, Smith T, Borden E, Blum RH. Interferon-α-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group EST 1694 trial. J. Clin. Oncol. 14, 7-17 (1996).
25. Mellado B, Colomer D, Castel T et al. Detection of circulating neoplastic cells by reverse-transcriptase polymerase chain reaction in malignant melanoma: association with clinical stage and prognosis. J. Clin. Oncol. 14, 2091-2097 (1996).
26. Mocellin S, Hoon D, Pilati P, Rossi CR, Nitti D. Sentinel lymph node molecular ultrastaging in patients with melanoma: a systematic review and meta-analysis. J. Clin. Oncol. 25, 1588-1595 (2007).